This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Alkermes plc (NASDAQ: ALKS) today announced that it has expanded its senior management team by appointing two industry veterans to newly created roles. Srdjan (Serge) Stankovic, M.D., MSPH, will serve as Senior Vice President of Clinical Development and Medical Affairs, and Peter Norman has joined the company as Vice President of Government Affairs and Policy.
“We are very pleased to welcome Serge and Pete – two proven leaders whose expertise will contribute to Alkermes’ next stage of growth,” said Richard Pops, Chief Executive Officer of Alkermes. “As our portfolio of new medicines expands, we are responding by strengthening our capabilities in two areas critical for our future: global clinical development and government affairs.”
Dr. Serge Stankovic will be responsible for Alkermes’ Clinical Development and Medical Affairs function, which advances and implements the clinical development programs for the company’s pipeline of drug candidates. He will serve on the senior management team at Alkermes and report to Elliot Ehrich, M.D., Senior Vice President of Research & Development and Chief Medical Officer.
“I am very enthusiastic about leading the clinical development programs during this exciting time when Alkermes is expanding its pipeline,” said Dr. Stankovic. “I look forward not only to making progress with the range of clinical studies that are underway and planned for drug candidates, but also to achieving the ultimate goal of delivering valuable medicines that make a difference for patients.”
Mr. Peter Norman will lead Alkermes’ U.S. Government Affairs and Policy function, ranging from activities at federal and state levels, to interactions with professional and patient organizations. He will serve on the senior management team at Alkermes and report to Kathryn Biberstein, Senior Vice President, Chief Legal Officer and Chief Compliance Officer.
“I am excited to join Alkermes at a time when there are so many emerging opportunities to connect the company’s medicines with policy and advocacy initiatives to impact patients, healthcare systems and the public health,” said Mr. Norman. “Alkermes is poised to advance innovative solutions for chronic central nervous system (CNS) diseases that significantly impact both health systems and society. I also look forward to exploring new public affairs and policy strategies for enhancing adoption of, and access to, the company’s products.”